Navigation Links
Resverlogix's Lead Drug Featured in Key Scientific Publication
Date:7/18/2008

RVX-208 is the only Apo-Al/HDL drug to be highlighted

TSX Exchange Symbol: RVX

CALGARY, July 18 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that Resverlogix's lead drug is featured prominently in an article titled "Emerging Antidyslipidemic Drugs", which appears in the current edition of Expert Opinion of Emerging Drugs, a well respected scientific journal for the pharmaceutical industry. The article written by Drs.' Pollex, Joy and Hegele provides an overview of current and upcoming dyslipidemic drugs.

"To be the only ApoA-l/HDL drug highlighted in an esteemed journal such as Expert Opinion of Emerging Drugs speaks volumes as to the excitement felt in the scientific community for our lead drug RVX-208," stated Donald McCaffrey, President and CEO of Resverlogix. "The data provided to the authors was our preclinical data. The Phase 1a data which we recently announced illustrated very similar trending as the African Green Monkey data of increased ApoA-I production and HDL functionality, thus our enthusiasm continues to build as we head into our Phase 1b/2a trial later this year."

RVX-208 is a first-in-class small molecule that facilitates endogenous ApoA-I production. It is positioned as one of the most promising emerging drugs in the treatment of atherosclerosis, the largest medical market in the world with a critical unmet need. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production. Consequently this raises functional HDL levels which in turn enhance reverse cholesterol transport, atherosclerosis regression and ultimately reduction of major adverse cardiovascular events (MACE).

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) pr
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. lifesDHA(TM) Featured in New Ricos(R) Cheese Sauce
2. Boydens Summit Practice Featured in the September Issue of New Jersey Business Magazine
3. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
4. Synvista Therapeutics to be Featured on Wallst.net
5. Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
7. Marteks lifesDHA(TM) Now Featured in Two New Flavors of Rachels(R) Wickedly Delicious Yogurt from WhiteWave Foods
8. CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
9. CT Laser Mammography Technology to be Featured at Interdisciplinary Breast Cancer Conference
10. Cord Blood America Subsidiary Featured at NASCAR Sprint Cup Series Race
11. CT Laser Mammography Technology to be Featured at European Congress of Radiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DALLAS , Sept. 18, 2014 /PRNewswire-iReach/ -- ... and China Acetic Acid Industry" and "2014 Deep ... Industry" reports to its research database. ... 2014 Deep Research Report on Global and China ... research report on China ...
(Date:9/18/2014)... Texas (PRWEB) September 18, 2014 ... Chancellor John Sharp, Texas A&M Health Science Center ... U.S. Department of Health and Human Services (HHS), ... dedicated a national pandemic influenza vaccine manufacturing facility ... as an anchor for the Texas A&M Biocorridor ...
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... Human Albumin Industry Report 2014" report to their ... Report 2014 is a professional and in-depth study on ... The report provides a basic overview of ... structure. The human albumin market analysis is provided for ...
(Date:9/18/2014)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... NewsMakers in the Biotech Industry conference on Friday, September ... Broadway Hotel & Conference Center in New York ... accessed at www.meipharma.com . A replay will be available ...
Breaking Biology Technology:Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... Boston Scientific,Corporation (NYSE: BSX ) today announced financial ... as guidance for net sales and,earnings per share (EPS) for ... -- Reported net sales of $1.978 billion and adjusted ... market leadership -- Achieved worldwide cardiac rhythm management (CRM) ...
... Holding Company to Strengthen ... Acquires Research and Product Development Company to Expedite Product ... ... at 8:00 am E.T., NEW YORK, Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, ...
... $165 Million Line of Credit to ... Amylin, ... ) and Eli Lilly and Company (NYSE: LLY ),today announced they have ... if approved, would,become the first once weekly therapy to treat type 2 diabetes. ...
Cached Biology Technology:Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27American Oriental Bioengineering Completes Two Acquisitions 2American Oriental Bioengineering Completes Two Acquisitions 3American Oriental Bioengineering Completes Two Acquisitions 4Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 2Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 3
(Date:9/18/2014)... 2014 New research into the Crimean-Congo hemorrhagic fever ... hemorrhagic disease in humans similar to that caused by ... infection. This discovery has the potential to lead to ... , The research, reported in a paper published ... conducted by scientists at the Texas Biomedical Research Institute ...
(Date:9/18/2014)... of Americans to undertake jaunts into the countryside each year ... within a century, according to new research. , Climate change ... United States as summer temperatures linger later into the year, ... and Biogeography . For instance, the paper birch a ... Hampshire could change color one to three weeks later ...
(Date:9/18/2014)... and ethnic groups describe losing eyesight as potentially ... more so than other conditions including: loss of ... 49% of non-Hispanic whites, 43% of Asians and ... ailment is the worst that could happen to ... AIDS/HIV. Hispanics and Asians ranked cancer first ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... Heart patients who can,t tolerate the side effects ... to a new study by researchers from the Intermountain ... City. Researchers found that pitavastatin, a newer cholesterol-lowering ... and even death in up to 68 percent of ...
... has identified a protein that can change DNA topology, making DNA ... new insight about the role of the proteinknown as mini-chromosome maintenance ... Think about twisting one end of a rubber band while holding ... neatly twisted rope. But if you keep on turning, the twisted ...
... the greatest mysteries of modern coral reefs is how they ... long existed in the record of coral evolution. This ... sea level and changes in the Earth,s climate between 1 ... "old" corals went extinct, and the modern reef corals emerged. ...
Cached Biology News:Researchers find alternative cholesterol-lowering drug for patients who can't tolerate statins 2Protein abundant in cancerous cells causes DNA 'supercoiling' 2University of Miami geologists to address the mystery of an evolution gap in reef corals 2
... Cell permeable fluorescent minor groove-binding probe ... of double-stranded DNA (preferentially to AT rich ... approximately 20 times greater than DAPI alone. ... ethidium bromide for staining DNA in agarose ...
... The 96 PW is an intelligent full ... washing all wells simultaneously. This instrument gives you ... and outstanding washing efficiency , Performance ... throughput and excellent wash efficiency. A dispense precision ...
... CE 4100 high pressure dual piston pump and ... for added flexibility. The system is ... unit, CE 4901., The CE 4901 PowerStream software ... with Windows 98 and 2000, offers the same ...
...
Biology Products: